Literature DB >> 3965079

Medulloblastoma. Period of risk reviewed.

J P Latchaw, J F Hahn, D J Moylan, R Humphries, J Mealey.   

Abstract

Collins postulated that patients with Wilms' tumor surviving for a period equal to their age at diagnosis plus 9 months were no longer at risk for a recurrence. Although this no longer holds for Wilms' tumor, it has been applied to patients with medulloblastoma. Case histories of patients who survived a period of risk designated by Collins' rule and later developed a histologically confirmed recurrent medulloblastoma are discussed. Reported cases violating Collins' rule constitute less than 2% of all medulloblastomas. The continued use of Collins' rule is advocated. Patients who have survived this period of risk, are neurologically stable, and have a negative computerized tomography (CT) head scan are exceedingly unlikely to develop a recurrent medulloblastoma.

Entities:  

Mesh:

Year:  1985        PMID: 3965079     DOI: 10.1002/1097-0142(19850101)55:1<186::aid-cncr2820550129>3.0.co;2-x

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Medulloblastoma: survival and late recurrence after the Collins' risk period.

Authors:  S Nishio; T Morioka; I Takeshita; M Fukui
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

2.  Brain tumors of childhood: nosological and diagnostic problems.

Authors:  D Schiffer; M T Giordana; M C Vigliani
Journal:  Childs Nerv Syst       Date:  1989-08       Impact factor: 1.475

3.  Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?

Authors:  E Bouffet; F Doz; M C Demaille; P Tron; H Roche; D Plantaz; A Thyss; J L Stephan; O Lejars; E Sariban; M Buclon; J M Zücker; M Brunat-Mentigny; J L Bernard; J C Gentet
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  Evaluation of desmin as a diagnostic and prognostic marker of childhood rhabdomyosarcomas and embryonal sarcomas.

Authors:  P Dias; P Kumar; H B Marsden; P H Morris-Jones; J Birch; R Swindell; S Kumar
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.